$1.01 Billion is the total value of Bellevue Group AG's 124 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 21.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CELG | Buy | CELGENE CORP | $38,753,000 | -8.1% | 434,400 | +7.5% | 3.84% | -12.9% |
| ABT | Buy | ABBOTT LABS | $33,855,000 | +11.9% | 565,000 | +6.6% | 3.35% | +6.1% |
| MDT | Buy | MEDTRONIC PLC | $28,639,000 | +63.4% | 357,000 | +64.5% | 2.84% | +54.9% |
| EW | Buy | EDWARDS LIFESCIENCES CORP | $27,508,000 | +29.7% | 197,160 | +4.8% | 2.72% | +23.0% |
| DXCM | Buy | DEXCOM INC | $26,430,000 | +72.7% | 356,390 | +33.6% | 2.62% | +63.7% |
| HUM | Buy | HUMANA INC | $22,501,000 | +172.0% | 83,700 | +151.0% | 2.23% | +158.0% |
| TDOC | Buy | TELADOC INC | $20,782,000 | +1168.7% | 515,694 | +997.2% | 2.06% | +1104.1% |
| ABC | Buy | AMERISOURCEBERGEN CORP | $18,550,000 | -4.2% | 215,178 | +2.0% | 1.84% | -9.1% |
| SYK | Buy | STRYKER CORP | $18,232,000 | +29.0% | 113,300 | +24.1% | 1.81% | +22.3% |
| VRTX | Buy | VERTEX PHARMACEUTICALS INC | $15,778,000 | +9.4% | 96,810 | +0.6% | 1.56% | +3.8% |
| ALXN | Buy | ALEXION PHARMACEUTICALS INC | $14,645,000 | -6.4% | 131,390 | +0.5% | 1.45% | -11.2% |
| IONS | Buy | IONIS PHARMACEUTICALS INC | $13,761,000 | +6.6% | 312,186 | +21.6% | 1.36% | +1.1% |
| SUPN | Buy | SUPERNUS PHARMACEUTICALS INC | $13,227,000 | +38.1% | 288,800 | +20.1% | 1.31% | +30.9% |
| CNC | Buy | CENTENE CORP DEL | $12,827,000 | +10.2% | 120,020 | +4.0% | 1.27% | +4.5% |
| KTWO | New | K2M GROUP HLDGS INC | $12,657,000 | – | 667,941 | +100.0% | 1.25% | – |
| ESPR | Buy | ESPERION THERAPEUTICS INC NEW | $12,493,000 | +2330.5% | 172,720 | +2114.4% | 1.24% | +2192.6% |
| FIT | New | FITBIT INCcl a | $11,707,000 | – | 2,295,400 | +100.0% | 1.16% | – |
| IART | Buy | INTEGRA LIFESCIENCES HLDGS C | $10,570,000 | +21.2% | 191,000 | +4.8% | 1.05% | +14.9% |
| RMD | Buy | RESMED INC | $10,536,000 | +164.7% | 107,000 | +127.7% | 1.04% | +151.0% |
| LH | Buy | LABORATORY CORP AMER HLDGS | $9,661,000 | +6.6% | 59,730 | +5.1% | 0.96% | +1.1% |
| HCM | Buy | HUTCHISON CHINA MEDITECH LTDsponsored adr | $8,940,000 | +70.0% | 302,420 | +125.9% | 0.89% | +61.4% |
| ALDR | Buy | ALDER BIOPHARMACEUTICALS INC | $8,896,000 | +2441.7% | 700,464 | +2189.1% | 0.88% | +2281.1% |
| SHPG | Buy | SHIRE PLCsponsored adr | $8,730,000 | -0.3% | 58,435 | +3.5% | 0.86% | -5.5% |
| TSRO | Buy | TESARO INC | $8,274,000 | +38.5% | 144,802 | +100.8% | 0.82% | +31.4% |
| ABMD | Buy | ABIOMED INC | $7,929,000 | +56.7% | 27,250 | +0.9% | 0.79% | +48.6% |
| INSM | New | INSMED INC | $7,533,000 | – | 334,489 | +100.0% | 0.75% | – |
| GNMK | Buy | GENMARK DIAGNOSTICS INC | $6,455,000 | +100.1% | 1,186,502 | +53.4% | 0.64% | +89.9% |
| CERN | Buy | CERNER CORP | $3,712,000 | +25.2% | 64,000 | +45.5% | 0.37% | +18.7% |
| BMY | New | BRISTOL MYERS SQUIBB CO | $2,530,000 | – | 40,000 | +100.0% | 0.25% | – |
| ICPT | Buy | INTERCEPT PHARMACEUTICALS IN | $1,962,000 | +73.2% | 31,900 | +64.4% | 0.19% | +64.4% |
| DVAX | Buy | DYNAVAX TECHNOLOGIES CORP | $1,876,000 | +82.3% | 94,500 | +71.8% | 0.19% | +73.8% |
| CLLS | Buy | CELLECTIS S Asponsored ads | $1,642,000 | +131.3% | 52,100 | +114.0% | 0.16% | +120.3% |
| VRX | New | VALEANT PHARMACEUTICALS INTL | $1,592,000 | – | 100,000 | +100.0% | 0.16% | – |
| AKCA | New | AKCEA THERAPEUTICS INC | $1,250,000 | – | 48,799 | +100.0% | 0.12% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Bellevue Asset Management AG #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IONIS PHARMACEUTICALS INC | 31 | Q3 2023 | 9.3% |
| Vertex Pharmaceuticals Incorporated | 31 | Q3 2023 | 5.9% |
| NEUROCRINE BIOSCIENCES INC | 31 | Q3 2023 | 5.7% |
| Incyte Corporation | 31 | Q3 2023 | 5.4% |
| INTUITIVE SURGICAL INC | 31 | Q3 2023 | 4.7% |
| ABBOTT LABS | 31 | Q3 2023 | 4.6% |
| ELEVANCE HEALTH INC | 31 | Q3 2023 | 4.3% |
| UnitedHealth Group Incorporated | 31 | Q3 2023 | 3.6% |
| ALNYLAM PHARMACEUTICALS INC | 31 | Q3 2023 | 3.7% |
| Boston Scientific Corporation | 31 | Q3 2023 | 2.5% |
View Bellevue Group AG's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-02-14 |
| SC 13G | 2023-02-14 |
View Bellevue Group AG's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.